Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00638391

Acronym

Ax-003

Enrollment

1600

Registered

2008-03-19

Start date

2005-05-31

Completion date

2007-03-31

Last updated

2008-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Primary early MCa, Arimidex

Brief summary

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Interventions

DRUGAnastrozole

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions	12 months

Secondary

Measure	Time frame
description of population treated with anastrozole	12 months
further information about the change of specific laboratory parameters	12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026